Peritoneal effluent MMP-2 and PAI-1 in encapsulating peritoneal sclerosis

Area of Science:

• Nephrology
• Biomarker Discovery
• Peritoneal Dialysis Research

Background:

• Peritoneal fibrosis is a complication of peritoneal dialysis (PD).
• Matrix metalloproteinase 2 (MMP-2) and plasminogen activator inhibitor 1 (PAI-1) have been suggested as biomarkers for peritoneal fibrosis.
• This study investigates MMP-2 and PAI-1 as early diagnostic markers for encapsulating peritoneal sclerosis (EPS) in PD patients.

Purpose of the Study:

• To evaluate effluent MMP-2 and PAI-1 as early diagnostic markers for EPS.
• To assess the predictive value of these biomarkers in the years preceding EPS diagnosis.

Main Methods:

• A case-control study comparing PD patients who developed EPS with controls.
• Dialysate samples were analyzed for MMP-2 and PAI-1 appearance rates.
• EPS diagnosis was confirmed by expert nephrologists and a radiologist.

Main Results:

• No significant difference in MMP-2 appearance rates was found between EPS cases and controls up to 4 years before diagnosis.
• PAI-1 appearance rates were significantly higher in patients who developed EPS (P=0.01).
• PAI-1 showed fair discriminative ability (AUC=0.77) for EPS prediction at 1 year prior to diagnosis.

Conclusions:

• Elevated effluent PAI-1 levels are associated with progressive peritoneal fibrosis and EPS development.
• Effluent PAI-1 may serve as a valuable biomarker for monitoring peritoneal fibrosis and aiding in early EPS diagnosis.
• Further validation is needed due to the low event rate of EPS in this single-center study.